Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities
Open accessThe DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Abstract
Chronic and excessive inflammation in skin and joints causes significant morbidity in psoriasis patients. As a prevalent T lymphocyte-mediated disorder, psoriasis, as well as the side effects associated with its treatment, affects patients globally. In this review, recent progress is discussed in the areas of genetics, the immunological synapse, the untangling of the cytokine web and signaling pathways, xenotransplantation models, and the growing use of selectively targeted therapies. Since psoriasis is currently incurable, new management strategies are proposed to replace previous serendipitous approaches. Such strategic transition from serendipity to the use of novel selective agents aimed at defined targets in psoriatic lesions is moving rapidly from research benches to the bedsides of patients with this chronic and debilitating disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The development of psoriatic plaques is accompanied by activation of CD4 + T cells and other immune cells, which provide a plethora of cytokines and chemokines, including TNF and IFNγ 136”
From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [136]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
Hugot, J.-P., Chamaillard, M., Zouali, H., Lesage, S., Cézard, J.-P., Belaiche, J., Almer, S., Tysk, C., O'Morain, C. A., Gassull, M., et al. (2001) · Nature · doi:10.1038/35079107 · Cited by 5,591
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
Ogura, Y., Bonen, D. K., Inohara, N., Nicolae, D. L., Chen, F. F., Ramos, R., Britton, H., Moran, T., Karaliuskas, R., Duerr, R. H., et al. (2001) · Nature · doi:10.1038/35079114 · Cited by 5,030
The Danger Model: A Renewed Sense of Self
Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205 · cited 1×
“in keratinocytes to create a “danger signal” is unclear (51), but several possible molecular events may occur to activate resting dendritic APCs (52), followed by delivery of an antigenic signal”
BackgroundPoints of control in inflammation
Nathan, C. (2002) · Nature · doi:10.1038/nature01320 · Cited by 2,738 · cited 1×
“ic inflammatory diseases, HMGB1 is also considered an important regulator (67).”
BackgroundHuman epithelial cells trigger dendritic cell–mediated allergic inflammation by producing TSLP
Soumelis, V., Reche, P. A., Kanzler, H., Yuan, W., Edward, G., Homey, B., Gilliet, M., Ho, S., Antonenko, S., Lauerma, A., et al. (2002) · Nature Immunology · doi:10.1038/ni805 · Cited by 2,183 · cited 10×
“The successful use of cyclosporin, which acts to block cytokine release, resulted in a paradigm shift away from epidermal keratinocytes to various immunocyte populations including T cell subsets and dendritic APCs.”
BackgroundInfluentialAggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F. J., & Gurney, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207577200 · Cited by 1,847
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
Mease, P. J., Goffe, B. S., Metz, J., VanderStoep, A., Finck, B., & Burge, D. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02530-7 · Cited by 1,446 · cited 1×
“binds TNF-α and improves psoriatic arthritis and skin lesions (93, 94); and onercept, which improves Crohn disease (95).”
Backgroundp38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases
Kumar, S., Boehm, J., & Lee, J. C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1177 · Cited by 1,197 · cited 1×
“small molecules that can interfere with inflammatory responses mediated by p38 signaling (106), cytokine receptors (107), or rationally designed dominant negative TNF-α variants (108).”
BackgroundEtanercept as Monotherapy in Patients with Psoriasis
Leonardi, C. L., Powers, J. L., Matheson, R. T., Goffe, B. S., Zitnik, R., Wang, A., & Gottlieb, A. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030409 · Cited by 1,175 · cited 1×
“binds TNF-α and improves psoriatic arthritis and skin lesions (93, 94); and onercept, which improves Crohn disease (95).”
BackgroundWeitz-Schmidt, G., Welzenbach, K., Brinkmann, V., Kamata, T., Kallen, J., Bruns, C., Cottens, S., Takada, Y., & Hommel, U. (2001) · Nature Medicine · doi:10.1038/89058 · Cited by 1,041
Psoriasis of early and late onset: Characterization of two types of psoriasis vulgaris
Henseler, T., & Christophers, E. (1985) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(85)70188-0 · Cited by 1,005 · cited 1×
“Psoriasis can begin at any age, although epidemiological studies demonstrate that it most commonly appears for the first time between the ages of 15 and 25 years (3).”
BackgroundBromley, S. K., Burack, W. R., Johnson, K. G., Somersalo, K., Sims, T. N., Sumen, C., Davis, M. M., Shaw, A. S., Allen, P. M., & Dustin, M. L. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.375 · Cited by 979
Krueger, G. G., Koo, J. Y. M., Lebwohl, M., Menter, A., Stern, R. S., & Rolstad, T. (2001) · PubMed · Cited by 969
Lee, E., Trepicchio, W. L., Oestreicher, J. L., Pittman, D., Wang, F., Chamian, F., Dhodapkar, M., & Krueger, J. G. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20030451 · Cited by 899
Sakaguchi, N., Takahashi, T., Hata, H., Nomura, T., Tagami, T., Yamazaki, S., Sakihama, T., Matsutani, T., Negishi, I., Nakatsuru, S., et al. (2003) · Nature · doi:10.1038/nature02119 · Cited by 878 · cited 1×
“(42) reported a strain of mice that spontaneously develop a chronic systemic inflammatory disease resembling RA.”
Backgroundγ-Secretase-mediated proteolysis in cell-surface-receptor signalling
Fortini, M. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm910 · Cited by 824
Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease
Rioux, J. D., Daly, M. J., Silverberg, M. S., Lindblad, K., Steinhart, H., Cohen, Z., Delmonte, T., Kocher, K., Miller, K., Guschwan, S., et al. (2001) · Nature Genetics · doi:10.1038/ng1001-223 · Cited by 774 · cited 1×
“is 5q31, a locus also implicated in Crohn disease (47).”
BackgroundProkunina, L., Castillejo-López, C., Öberg, F., Gunnarsson, I., Berg, L., Magnusson, V., Brookes, A. J., Tentler, D., Kristjansdóttir, H., Gröndal, G., et al. (2002) · Nature Genetics · doi:10.1038/ng1020 · Cited by 769 · cited 4×
“However, current treatments include a new wave of selective therapeutic Nonstandard abbreviations used: Food and Drug Administration (FDA); highmobility group B1 (HMGB1); NK type T cell (NKT cell); programmed cell death 1 (gene) (PDCD1); regulatory single-nucleotide polymorphism (rSNP); rheumatoid arthritis (RA); rece…”
BackgroundInfluentialDisease concomitance in psoriasis
Henseler, T., & Christophers, E. (1995) · Journal of the American Academy of Dermatology · doi:10.1016/0190-9622(95)91336-x · Cited by 678
Tokuhiro, S., Yamada, R., Chang, X., Suzuki, A., Kochi, Y., Sawada, T., Suzuki, M., Nagasaki, M., Ohtsuki, M., Ono, M., et al. (2003) · Nature Genetics · doi:10.1038/ng1267 · Cited by 626
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor
Changelian, P. S., Flanagan, M. E., Ball, D. J., Kent, C. R., Magnuson, K. S., Martin, W. H., Rizzuti, B. J., Sawyer, P. S., Perry, B. D., Brissette, W. H., et al. (2003) · Science · doi:10.1126/science.1087061 · Cited by 607 · cited 1×
“small molecules that can interfere with inflammatory responses mediated by p38 signaling (106), cytokine receptors (107), or rationally designed dominant negative TNF-α variants (108).”
BackgroundGottlieb, S. L., Gilleaudeau, P., Johnson, R., Estes, L., Woodworth, T. G., Gottlieb, A. B., & Krueger, J. G. (1995) · Nature Medicine · doi:10.1038/nm0595-442 · Cited by 606
The immunologic basis for the treatment of psoriasis with new biologic agents
Krueger, J. G. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.120568 · Cited by 600 · cited 11×
“In addition, nitric oxide is present, which may contribute to an angiogenic tissue reaction, accompanied by many growth factors present at elevated levels within psoriatic plaques, including TGF-α, IGF-1, keratinocyte growth factor (KGF), VEGF, nerve growth factor (NGF), amphiregulin, and IL-20 (4).”
BackgroundInfluentialThe Natural History of Psoriasis in 5,600 Patients
Farber, E. M., & Nall, L. (1974) · Dermatology · doi:10.1159/000251595 · Cited by 599 · cited 1×
“with multiple afflicted family members (20), a search for the genetic basis of psoriasis began.”
BackgroundTreatment of Chronic Plaque Psoriasis by Selective Targeting of Memory Effector T Lymphocytes
Ellis, C. N., & Krueger, G. G. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107263450403 · Cited by 582 · cited 1×
“example, an LFA-3 Ig fusion protein (alefacept) has been found to reduce psoriatic lesions (36), and a different fusion protein, CTLA4Ig,”
BackgroundA Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis
Lebwohl, M., Tyring, S. K., Hamilton, T. K., Toth, D., Glazer, S., Tawfik, N. H., Walicke, P., Dummer, W., Wang, X., Garovoy, M. R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030002 · Cited by 570 · cited 1×
“been approved by the US Food and Drug Administration (FDA) for the treatment of psoriasis (34).”
BackgroundBlumberg, H., Conklin, D., Xu, W., Grossmann, A., Brender, T., Carollo, S., Eagan, M., Foster, D., Haldeman, B. A., Hammond, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00187-8 · Cited by 547 · cited 3×
“T cells are the likely source for IFN-γ, IL-15 (71, 72), and IL-17 (73), whereas keratinocytes can produce IL-1, IL-6, and IL-8, as well as IL-18 (74) and IL-20 (75).”
Crohn’s disease and the NOD2 gene: a role for paneth cells
Lala, S., Ogura, Y., Osborne, C., Hor, S. Y., Bromfield, A., Davies, S., Ogunbiyi, O., Nuñez, G., & Keshav, S. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00661-9 · Cited by 528 · cited 1×
“which are most numerous in the terminal ileum (104).”
BackgroundBoyman, O., Hefti, H. P., Conrad, C., Nickoloff, B. J., Suter, M., & Nestle, F. O. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031482 · Cited by 522 · cited 1×
“This animal model uses AGR129 mice (which are deficient in type I and type II IFN receptors) and has recombination-activating gene 2 knocked out (87).”
MethodSelf-citationTrembath, R. C., Lee Clough, R., Rosbotham, J. L., Jones, A. B., Camp, R. D. R., Frodsham, A., Browne, J., Barber, R., Terwilliger, J., Mark Lathrop, G., et al. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.5.813 · Cited by 508 · cited 1×
“Several other psoriasis-susceptibility loci have been mapped, including PSORS7 (1p) and PSORS9 (4q31), and additional studies are ongoing by many laboratories (24, 25) and the International Psoriasis Genetics Consortium (26).”
Backgroundl -Arginine Consumption by Macrophages Modulates the Expression of CD3ζ Chain in T Lymphocytes
Rodriguez, P. C., Zea, A. H., DeSalvo, J., Culotta, K. S., Zabaleta, J., Quiceno, D. G., Ochoa, J. B., & Ochoa, A. C. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1232 · Cited by 492 · cited 1×
“found to influence L-arginine levels, this could, in turn, modulate extracellular levels of nitric oxide and thereby alter TCR-ζ chain expression (49), providing a further link between the genetics of autoimmunity and the immunological synapse.”
BackgroundNickoloff, B. J., & Naidu, Y. (1994) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(94)70059-1 · Cited by 459 · cited 1×
“(53); exposure of DCs constitutively expressing MHC class II molecules such as HLA-DR in the epidermis and/or dermis to”
BackgroundSelf-citationT Cells Involved in Psoriasis Vulgaris Belong to the Th1 Subset
Schlaak, J. F., Buslau, M., Jochum, W., Hermann, E., Girndt, M., Gallati, H., Büschenfelde, K.-H. M. Z., & Fleischer, B. (1994) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12371752 · Cited by 455 · cited 1×
“with rather limited cytokine analysis revealed a Th1-type profile (61, 62).”
BackgroundInterleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease
Ghoreschi, K., Thomas, P., Breit, S., Dugas, M., Mailhammer, R., van Eden, W., van der Zee, R., Biedermann, T., Prinz, J., Mack, M., et al. (2003) · Nature Medicine · doi:10.1038/nm804 · Cited by 453 · cited 2×
“IFN-γ, TNF-α, and IL-12, but not IL-4, IL-5, or IL-10, were documented within psoriatic plaques at the mRNA and protein levels.”
Uyemura, K., Yamamura, M., Fivenson, D. F., Modlin, R. L., & Nickoloff, B. J. (1993) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12371679 · Cited by 450 · cited 1×
“with rather limited cytokine analysis revealed a Th1-type profile (61, 62).”
BackgroundSelf-citationDermal injection of immunocytes induces psoriasis.
Wrone-Smith, T., & Nickoloff, B. J. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118989 · Cited by 439 · cited 1×
“use of animal models in which human skin was engrafted onto SCID mice (78, 79).”
MethodSelf-citationCellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis.
Nickoloff, B. J., Karabin, G. D., Barker, J. N., Griffiths, C. E. M., Sarma, V. J., Mitra, R. S., Elder, J. T., Kunkel, S. L., & Dixit, V. M. (1991) · PubMed Central · Cited by 430
Self-citationGene for Familial Psoriasis Susceptibility Mapped to the Distal End of Human Chromosome 17q
Tomfohrde, J., Silverman, A., Barnes, R., Fernandez-Vina, M. A., Young, M., Lory, D., Morris, L., Wuepper, K. D., Stastny, P., Menter, A., et al. (1994) · Science · doi:10.1126/science.8178173 · Cited by 426 · cited 1×
“Linkage of psoriasis to this locus has been identified by independent family sets (30, 31).”
BackgroundAsadullah, K., Sterry, W., Stephanek, K., Jasulaitis, D., Leupold, M., Audring, H., Volk, H. D., & Döcke, W. D. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1476 · Cited by 415 · cited 5×
“Proof of principle by IL-10 therapy: a new therapeutic approach.”
InfluentialNair, R. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.8.1349 · Cited by 404 · cited 1×
“Several other psoriasis-susceptibility loci have been mapped, including PSORS7 (1p) and PSORS9 (4q31), and additional studies are ongoing by many laboratories (24, 25) and the International Psoriasis Genetics Consortium (26).”
BackgroundPsoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens?
Valdimarsson, H., Baker, B. S., Jónsdóttir, I., Powles, A., & Fry, L. (1995) · Immunology Today · doi:10.1016/0167-5699(95)80132-4 · Cited by 358
The Cytokine Network in Psoriasis
Nickoloff, B. J. (1991) · Archives of Dermatology · doi:10.1001/archderm.127.6.871 · Cited by 344 · cited 3×
“challenging task of integrating the in vitro and in vivo findings into a coherent cytokine network that had spatial and temporal validity was first undertaken in 1991 (17).”
BackgroundMethodSelf-citationMartin, M. P., Nelson, G., Lee, J.-H., Pellett, F., Gao, X., Wade, J., Wilson, M. J., Trowsdale, J., Gladman, D., & Carrington, M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.6.2818 · Cited by 328
Abrams, J. R., Kelley, S. L., Hayes, E., Kikuchi, T., Brown, M. J., Kang, S., Lebwohl, M. G., Guzzo, C. A., Jegasothy, B. V., Linsley, P. S., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.5.681 · Cited by 318
Yabuuchi, H., Tamai, I., Nezu, J.-I., Sakamoto, K., Oku, A., Shimane, M., Sai, Y., & Tsuji, A. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38199-6 · Cited by 316 · cited 3×
“L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes.”
BackgroundNestle, F. O., Turka, L. A., & Nickoloff, B. J. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117308 · Cited by 306
Self-citationTIILIKAINEN, A., LASSUS, A., KARVONEN, J., VARTIAINEN, P., & JULIN, M. (1980) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1980.tb05690.x · Cited by 303 · cited 7×
“One of the earliest candidate genes for predisposition to psoriasis was the HLA class I allele, specifically HLACw6 (21).”
BackgroundInfluentialHelms, C., Cao, L., Krueger, J. G., Wijsman, E. M., Chamian, F., Gordon, D., Heffernan, M., Daw, J. A. W., Robarge, J., Ott, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1268 · Cited by 299 · cited 5×
“Two candidate genes in this region are SLC9A3R1 and NAT9, which are discussed in the following section (32).”
BackgroundInfluentialZhou, X., Krueger, J. G., Kao, M.-C. J., Lee, E., Du, F., Menter, A., Wong, W. H., & Bowcock, A. M. (2003) · Physiological Genomics · doi:10.1152/physiolgenomics.00157.2002 · Cited by 295
Albanesi, C., Scarponi, C., Cavani, A., Federici, M., Nasorri, F., & Girolomoni, G. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00041.x · Cited by 286 · cited 2×
“T cells are the likely source for IFN-γ, IL-15 (71, 72), and IL-17 (73), whereas keratinocytes can produce IL-1, IL-6, and IL-8, as well as IL-18 (74) and IL-20 (75).”
α4Integrins as Therapeutic Targets in Autoimmune Disease
von Andrian, U. H., & Engelhardt, B. (2003) · New England Journal of Medicine · doi:10.1056/nejme020157 · Cited by 276 · cited 1×
“nizes VCAM-1, and antibodies against VLA-4 improve multiple sclerosis and Crohn disease (100).”
BackgroundThe genetics of psoriasis: a complex disorder of the skin and immune system
Bhalerao, J. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.10.1537 · Cited by 274
Injection of Pre-Psoriatic Skin with CD4+ T Cells Induces Psoriasis
Nickoloff, B. J., & Wrone-Smith, T. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65109-7 · Cited by 260 · cited 1×
“The initial observation in which prepsoriatic skin was converted to psoriatic plaques using the SCID-Hu model suggested that CD4+ T cells, but not CD8+ T cells, were capable of triggering psoriasis (80).”
MethodSelf-citationInsights into psoriasis and other inflammatory diseases from large-scale gene expression studies
Bowcock, A. M. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.17.1793 · Cited by 258 · cited 2×
“cDNA-based microarrays, this list has grown exponentially (65, 66).”
BackgroundInactivation of TNF Signaling by Rationally Designed Dominant-Negative TNF Variants
Steed, P. M., Tansey, M. G., Zalevsky, J., Zhukovsky, E. A., Desjarlais, J. R., Szymkowski, D. E., Abbott, C., Carmichael, D., Chan, C., Cherry, L., et al. (2003) · Science · doi:10.1126/science.1081297 · Cited by 256 · cited 1×
“small molecules that can interfere with inflammatory responses mediated by p38 signaling (106), cytokine receptors (107), or rationally designed dominant negative TNF-α variants (108).”
BackgroundSignaling Life and Death in the Thymus: Timing Is Everything
Werlen, G., Hausmann, B., Naeher, D., & Palmer, E. (2003) · Science · doi:10.1126/science.1067833 · Cited by 250 · cited 1×
“org Volume 113 Number 12 June 2004 1669 been suggested that alterations in TCR signaling, which is critical for central tolerance (elimination of autoreactive T cells), may cause a breakdown in thymic negative selection and hence mediate appearance of autoreactive T cells (41).”
BackgroundThe pathophysiology of psoriasis
BARKER, J. (1991) · The Lancet · doi:10.1016/0140-6736(91)90357-u · Cited by 235
Saiag, P., Coulomb, B., Lebreton, C., Bell, E., & Dubertret, L. (1985) · Science · doi:10.1126/science.2413549 · Cited by 223 · cited 1×
“Other theories implicated psoriatic fibroblasts (8); neutrophils; mast cells (9); nerve cell endings (10); endothelial cells (11); T lymphocytes (12–14), and, specifically, clonal expansion of T cells (15, 16); and DCs (13).”
BackgroundBonish, B., Jullien, D., Dutronc, Y., Huang, B. B., Modlin, R., Spada, F. M., Porcelli, S. A., & Nickoloff, B. J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.7.4076 · Cited by 220 · cited 4×
“Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells.”
BackgroundInfluentialSelf-citationde Fougerolles, A. R., Sprague, A. G., Nickerson-Nutter, C. L., Chi-Rosso, G., Rennert, P. D., Gardner, H., Gotwals, P. J., Lobb, R. R., & Koteliansky, V. E. (2000) · Journal of Clinical Investigation · doi:10.1172/jci7911 · Cited by 218
Trepicchio, W. L., Ozawa, M., Walters, I. B., Kikuchi, T., Gilleaudeau, P., Bliss, J. L., Schwertschlag, U., Dorner, A. J., & Krueger, J. G. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6910 · Cited by 217 · cited 2×
“While anti-inflammatory effects of IL-10 and IL-11 were relatively modest compared with those of the TNF-α inhibitors, clearly the entire field is rapidly moving from nonspecific treatments such as arsenic, corticosteroids, methotrexate, and UV light to more selective treatments aimed at defined pathogenic targets for…”
The Immunologic and Genetic Basis of Psoriasis
Nickoloff, B. J. (1999) · Archives of Dermatology · doi:10.1001/archderm.135.9.1104 · Cited by 212 · cited 8×
“These possible events include perturbation of the barrier function of skin with release of preformed or rapidly produced cytokines such as IL-1 and TNF-α (53); exposure of DCs constitutively expressing MHC class II molecules such as HLA-DR in the epidermis and/or dermis to bacterial products from skin flora (54), incl…”
BackgroundMethodInfluentialSelf-citationInhibition of Keratinocyte Apoptosis by IL-15: A New Parameter in the Pathogenesis of Psoriasis?
Rückert, R., Asadullah, K., Seifert, M., Budagian, V. M., Arnold, R., Trombotto, C., Paus, R., & Bulfone-Paus, S. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.4.2240 · Cited by 211 · cited 5×
“Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis?”
InfluentialResolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model
Villadsen, L. S., Schuurman, J., Beurskens, F. J. M., Dam, T. N., Dagnæs‐Hansen, F., Skov, L., Rygaard, J., Voorhorst‐Ogink, M. M., Gerritsen, A. F., van Dijk, M. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18986 · Cited by 192 · cited 5×
“Inhibition of keratinocyte apoptosis by IL-15: a new parameter in the pathogenesis of psoriasis?”
InfluentialOestreicher, J. L., Walters, I. B., Kikuchi, T., Gilleaudeau, P., Surette, J., Schwertschlag, U., Dorner, A. J., Krueger, J. G., & Trepicchio, W. L. (2001) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500067 · Cited by 174 · cited 7×
“cDNA-based microarrays, this list has grown exponentially (65, 66).”
BackgroundInfluentialCARD15: a Pleiotropic Autoimmune Gene That Confers Susceptibility to Psoriatic Arthritis
Rahman, P., Bartlett, S., Siannis, F., Pellett, F. J., Farewell, V. T., Peddle, L., Schentag, C. T., Alderdice, C. A., Hamilton, S., Khraishi, M., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/378076 · Cited by 164 · cited 1×
“fers susceptibility to psoriatic arthritis (103).”
Reitamo, S., Spuls, P. I., Sassolas, B., Lahfa, M., Claudy, A., Griffiths, C. E. M., & FOR THE SIROLIMUS EUROPEAN PSORIASIS STUDY GROUP (2001) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2001.04376.x · Cited by 161 · cited 1×
“Other immunosuppressant drugs that block cytokine release and have been found to be effective in psoriasis include sirolimus (rapamycin) (89) and pimecro-”
BackgroundSearching for the Major Histocompatibility Complex Psoriasis Susceptibility Gene
Capon, F., Munro, M., Trembath, R., & Barker, J. (2002) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2002.01749.x · Cited by 159 · cited 8×
“Psoriasis and HLA-Cw6.”
BackgroundInfluentialItoh, K., Sakakibara, M., Yamasaki, S., Takeuchi, A., Arase, H., Miyazaki, M., Nakajima, N., Okada, M., & Saito, T. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.2.541 · Cited by 158 · cited 1×
“tion during development (central tolerance) and thus leading to the emergence of autoreactive T cells (46), or alter local immune”
BackgroundInnate Immune-Related Receptors in Normal and Psoriatic Skin
Curry, J. L., Qin, J.-Z., Bonish, B., Carrick, R., Bacon, P., Panella, J., Robinson, J., & Nickoloff, B. J. (2003) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2003-127-178-iirrin · Cited by 157
Self-citationQuinones, M. P., Ahuja, S. K., Jimenez, F., Schaefer, J., Garavito, E., Rao, A., Chenaux, G., Reddick, R. L., Kuziel, W. A., & Ahuja, S. S. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420126 · Cited by 149
Nickoloff, B. J., Bonish, B. K., Huang, B. B., & Porcelli, S. A. (2000) · Journal of Dermatological Science · doi:10.1016/s0923-1811(00)00120-1 · Cited by 143 · cited 1×
“dence for a possible role of NKT cells in the immunopathogenesis of psoriasis (82, 83).”
BackgroundSelf-citationPulling the trigger on psoriasis
Boehncke, W., Dressel, D., Zollner, T. M., & Kaufmann, R. (1996) · Nature · doi:10.1038/379777a0 · Cited by 141 · cited 1×
“use of animal models in which human skin was engrafted onto SCID mice (78, 79).”
MethodLomholt, G., & Cour, A. L. (1963) · G.E.C. Gad eBooks · Cited by 139
Gottlieb, A. B., Lebwohl, M., Shirin, S., Sherr, A., Gilleaudeau, P., Singer, G., Solodkina, G., Grossman, R., GISOLDI, E., Phillips, S., et al. (2000) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2000.107945 · Cited by 132 · cited 1×
“(39), and a fusion protein containing the cell-binding domain of diphtheria toxin (i.”
BackgroundSchön, M. P., Krahn, T., Schön, M., Rodriguez, M.-L., Antonicek, H., Schultz, J. E., Ludwig, R. J., Zollner, T. M., Bischoff, E., Bremm, K. D., et al. (2002) · Nature Medicine · doi:10.1038/nm0402-366 · Cited by 126
Hewett, D. R., Samuelsson, L., Polding, J., Enlund, F., Smart, D. H., Cantone, K. L., See, C. G., Chadha, S., Inerot, A., Enerbäck, C., et al. (2002) · Genomics · doi:10.1006/geno.2002.6720 · Cited by 120
Skin innate immune system in psoriasis: friend or foe?
Nickoloff, B. J. (1999) · Journal of Clinical Investigation · doi:10.1172/jci8633 · Cited by 120 · cited 1×
“innate immunity in psoriatic lesions (29).”
Self-citationReynolds, N. J., & Al-Daraji, W. I. (2002) · Clinical and Experimental Dermatology · doi:10.1046/j.1365-2230.2002.01148.x · Cited by 118 · cited 1×
“Another calcineurin inhibitor is tacrolimus, which is 50–100 times more potent than cyclosporin A (88).”
BackgroundGudjonsson, J. E., Kárason, A., Antonsdóttir, A. A., Rúnarsdóttir, E. H., Hauksson, V. B., Upmanyu, R., Gulcher, J. R., Stefánsson, K., & Valdimarsson, H. (2003) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2003.05115.x · Cited by 118 · cited 1×
“Also, homozygous individuals experience an earlier onset, but not necessarily a more severe disease course (22).”
BackgroundRappersberger, K., Komar, M., Richter, L., Wolff, K. S., Ebelin, M., Scott, G., Burtin, P., Greig, G., Kehren, J., Chibout, S., et al. (2002) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2002.00694.x · Cited by 113
Reich, K., Mößner, R., Neumann, C. R., König, I. R., Westphal, G., & Ziegler, A. (2002) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2001.01642.x · Cited by 113
Zollner, T. M., Podda, M., Pien, C. S., Elliott, P. J., Kaufmann, R., & Boehncke, W. (2002) · Journal of Clinical Investigation · doi:10.1172/jci12736 · Cited by 105
* (2003) · The American Journal of Human Genetics · doi:10.1086/377159 · Cited by 98
Immunologic mechanisms in psoriasis
Gottlieb, A. B. (1988) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(88)70145-0 · Cited by 98
Rutgeerts, P., Lemmens, L., Assche, G. V., Noman, M., Borghini-Fuhrer, I., & Goedkoop, R. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01414.x · Cited by 98 · cited 1×
“binds TNF-α and improves psoriatic arthritis and skin lesions (93, 94); and onercept, which improves Crohn disease (95).”
BackgroundKrueger, G. G., Bergstresser, P. R., Lowe, N. J., Voorhees, J. J., & Weinstein, G. D. (1984) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(84)80018-3 · Cited by 98
Expression of IL-18 in psoriasis
Ohta, Y., Hamada, Y., & Katsuoka, K. (2001) · Archives of Dermatological Research · doi:10.1007/s004030100240 · Cited by 95 · cited 3×
“Expression of IL-18 in psoriasis.”
Zollner, T. M., Podda, M., Pien, C., Elliott, P. J., Kaufmann, R., & Boehncke, W.-H. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0212736 · Cited by 94
Mast cells in psoriatic skin are strongly positive for interferon-gamma
ACKERMANN, HARVIMA, PELKONEN, RITAMÄKI-SALO, Naukkarinen, V., HARVIMA, & Horsmanheimo (1999) · British Journal of Dermatology · doi:10.1046/j.1365-2133.1999.02760.x · Cited by 92 · cited 1×
“Other theories implicated psoriatic fibroblasts (8); neutrophils; mast cells (9); nerve cell endings (10); endothelial cells (11); T lymphocytes (12–14), and, specifically, clonal expansion of T cells (15, 16); and DCs (13).”
BackgroundSpeckman, R. A., Daw, J., Helms, C., Duan, S., Cao, L. H., Taillon‐Miller, P., Kwok, P., Menter, A., & Bowcock, A. M. (2003) · Human Genetics · doi:10.1007/s00439-002-0851-y · Cited by 90 · cited 1×
“Linkage of psoriasis to this locus has been identified by independent family sets (30, 31).”
BackgroundGilhar, A., Ullmann, Y., Assy, B., Shalaginov, R., Serafimovich, S., Kerner, H., & Kalish, R. S. (2002) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2002.01812.x · Cited by 89 · cited 1×
“dence for a possible role of NKT cells in the immunopathogenesis of psoriasis (82, 83).”
BackgroundVollmer, S., Menssen, A., & Prinz, J. C. (2001) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2001.01494.x · Cited by 87
Nickoloff, B. J. (2001) · Journal of Cutaneous Pathology · doi:10.1034/j.1600-0560.2001.280201.x · Cited by 78 · cited 1×
“yet these sites almost never develop into, or harbor, malignant clones of keratinocytes, melanocytes, or T cells (5); (b) Despite significantly altered barrier function due to aberrant epidermal”
BackgroundSelf-citationRemission of psoriatic lesions with muromonab-CD3 (Orthoclone OKT3) treatment
Weinshenker, B. G., Bass, B. H., Ebers, G. C., & Rice, G. P. (1989) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(89)80200-2 · Cited by 78 · cited 5×
“Remission of psoriatic lesions with muromonab-CD3 (orthoclone OKT3) treatment.”
BackgroundInfluentialAdalimumab (HUMIRA): a review.
Scheinfeld, N. S. (2003) · PubMed · Cited by 76
Epidermal HLA-DR and the enhancement of cutaneous reactivity to superantigenic toxins in psoriasis
Travers, J. B., Hamid, Q. A., Norris, D. A., Kuhn, C. A., Giorno, R. C., Schlievert, P. M., Farmer, E. R., & Leung, D. Y. M. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6835 · Cited by 71 · cited 1×
“bacterial products from skin flora (54), including superantigens (55); release of heat shock proteins from epidermal keratinocytes”
BackgroundCD1d is Expressed on Dermal Dendritic Cells and Monocyte-Derived Dendritic Cells
Gerlini, G., Hefti, H. P., Kleinhans, M., Nickoloff, B. J., Burg, G., & Nestle, F. O. (2001) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2001.01458.x · Cited by 70 · cited 4×
“Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells.”
BackgroundInfluentialSelf-citationKess, D., Peters, T., Zamek, J., Wickenhauser, C., Tawadros, S., Loser, K., Varga, G., Grabbe, S., Nischt, R., Sunderkötter, C., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.5697 · Cited by 58
Persistence of T-Cell Clones in Psoriatic Lesions
Chang, J. C. C. (1997) · Archives of Dermatology · doi:10.1001/archderm.133.6.703 · Cited by 54
Ishihara, M., Yamagata, N., Ohno, S., Naruse, T. K., Ando, A., Kawata, H., Ozawa, A., Ohkido, M., Mizuki, N., Shiina, T., et al. (1996) · Tissue Antigens · doi:10.1111/j.1399-0039.1996.tb02626.x · Cited by 52 · cited 1×
“The two most likely candidate loci are HLA-Cw*0602 and the corneodesmosin gene (27), which encodes an adhesive protein expressed by keratinocytes and is important in terminal differen-”
BackgroundA RUNX trio with a taste for autoimmunity
Alarcón-Riquelme, M. E. (2003) · Nature Genetics · doi:10.1038/ng1203-299 · Cited by 51 · cited 1×
“polymorphisms in regulatory (promoter) regions of genes that impact proper immune synapse function with emergence of autoreactive T cells (43).”
BackgroundLOWE, P. M., LEE, M.-L., JACKSON, C. J., TO, S. S. T., COOPER, A. J., & SCHRIEBER, L. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1995.tb08702.x · Cited by 49 · cited 1×
“Other theories implicated psoriatic fibroblasts (8); neutrophils; mast cells (9); nerve cell endings (10); endothelial cells (11); T lymphocytes (12–14), and, specifically, clonal expansion of T cells (15, 16); and DCs (13).”
BackgroundZeigler, M. E., Chi, Y., Tumas, D. B., Bodary, S. C., Tang, H., & Varani, J. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780339 · Cited by 47
Interleukin-10 Promoter Polymorphism in Psoriasis
Asadullah, K., Wiese, A., Friedrich, M., Sterry, W., Eskdale, J., & Gallagher, G. E. (2001) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2001.01350.x · Cited by 47 · cited 1×
“have been identified for TNF-α and other inflammatory mediators (63, 64).”
BackgroundBaker, B. S., Brown, D. W., Fischetti, V. A., Ovigne, J. ‐., Porter, W. M., Powles, A. V., & Fry, L. (2001) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2001.01563.x · Cited by 44 · cited 1×
“bacterial products from skin flora (54), including superantigens (55); release of heat shock proteins from epidermal keratinocytes”
BackgroundInfliximab for psoriasis and psoriatic arthritis.
Antoni, C., & Manger, B. (2002) · PubMed · Cited by 39
Nickoloff, B. J., Mitra, R. S., Green, J. M., Shimizu, Y., Thompson, C. B., & Turka, L. A. (1993) · Journal of Dermatological Science · doi:10.1016/0923-1811(93)90002-7 · Cited by 31 · cited 2×
“The figure emphasizes costimulatory pathways involving CD2:LFA-3 and LFA-1:ICAM-1.”
BackgroundSelf-citationNEUROPATHOGENESIS AND NEUROPHARMACOLOGY OF PSORIASIS
Raychaudhuri, S. P., Rein, G., & Farber, E. M. (1995) · International Journal of Dermatology · doi:10.1111/j.1365-4362.1995.tb04653.x · Cited by 30 · cited 1×
“Other theories implicated psoriatic fibroblasts (8); neutrophils; mast cells (9); nerve cell endings (10); endothelial cells (11); T lymphocytes (12–14), and, specifically, clonal expansion of T cells (15, 16); and DCs (13).”
BackgroundCurry, J. L., Qin, J., Robinson, J. K., & Nickoloff, B. J. (2003) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2003-127-0289-roriin · Cited by 29
Self-citation
Research works printed but not linked: 6
- Krueger, 2001, Arch. Dermatol., 137, 280
- Yabuuchi, 1999, J. Pharmacol. Exp. Ther., 289, 768
- Nickoloff, 1991, Am. J. Pathol., 138, 129
- Villadsen, 2003, J. Clin. Invest., 112, 1571, 10.1172/JCI200318986 · doi:10.1172/jci200318986 · Paper page
- Antoni, 2002, Clin. Exp. Rheumatol., 20(Suppl. 28), S122
- Scheinfeld, 2003, J. Drugs Dermatol., 2, 375
Cited by
Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide
Lande, R., Gregorio, J., Facchinetti, V., Chatterjee, B., Wang, Y.-H., Homey, B., Cao, W., Wang, Y.-H., Su, B., Nestle, F. O., et al. (2007) · Nature · doi:10.1038/nature06116 · Cited by 1,910
Self-citationInterleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis
Zheng, Y., Danilenko, D. M., Valdez, P., Kasman, I., Eastham-Anderson, J., Wu, J., & Ouyang, W. (2007) · Nature · doi:10.1038/nature05505 · Cited by 1,862
Pathogenesis and therapy of psoriasis
Lowes, M. A., Bowcock, A. M., & Krueger, J. G. (2007) · Nature · doi:10.1038/nature05663 · Cited by 1,778
Plasmacytoid predendritic cells initiate psoriasis through interferon-α production
Nestle, F. O., Conrad, C., Tun-Kyi, A., Homey, B., Gombert, M., Boyman, O., Burg, G., Liu, Y.-J., & Gilliet, M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050500 · Cited by 1,124
“Although it is still unclear how these environmental factors drive the pathogenic T cell cascade, it has been suggested that innate immune pathways may provide the missing link (6, 7).”
BackgroundSelf-citationReich, K., Nestle, F. O., Papp, K., Ortonne, J.-P., Evans, R., Guzzo, C., Li, S., Dooley, L. T., & Griffiths, C. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67566-6 · Cited by 1,045
Self-citation
Metadata
- Authors
- Nickoloff, B. J., & Nestle, F. O.
- Affiliations
- Loyola University Medical Center (US)
- University of Zurich (CH)
- Corresponding author
- Nickoloff, Brian J.
- Venue
- Journal of Clinical Investigation
- Published
- 2004-06-15
- Volume
- 113
- Issue
- 12
- Pages
- 1664-1675
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC420513
- OpenAlex
- W2024387258
- Cited by
- 544
- References
- 110
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 9 · 2023: 11 · 2022: 23 · 2021: 18 · 2020: 10 · 2019: 23 · 2018: 18 · 2017: 17 · 2016: 19 · 2015: 24 · 2014: 26 · 2013: 29 · 2012: 27
- FWCI
- 19.28
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- Doris Duke Charitable Foundation
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR40065, R01AR040065)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
- Keywords
- psoriasis, immunopathogenesis, T cells, immunological synapse, cytokine signaling pathways, xenotransplantation model, targeted therapy, psoriasis genetics, chronic skin inflammation, psoriatic arthritis
- MeSH terms
- Animals, Dermatologic Agents, Disease Models, Animal, Disease Susceptibility, Humans, Immune System, Psoriasis, T-Lymphocytes, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.